RALLYBIO CORP

Rallybio, a clinical‑stage biotech targeting rare diseases, faces volatile stock, a $85M market cap, and a negative P/E—investors must weigh its high‑risk, high‑potential future.

Rallybio Corp withdraws SEC filing after merger collapse, refocusing on rare disease therapies while managing financial risks.

Rallybio Corporation, a clinical‑stage biotech focused on rare disease therapies, trades on Nasdaq, offering investors insight into its R&D progress and future value potential.

Rallybio Corporation is a clinical-stage biotech company focused on developing therapies for severe and rare diseases, with a promising pipeline and strategic initiatives that position it for significant growth in the healthcare sector.